AI-designed drug hints at reversing aging signals in IPF patients
TL;DR Summary
In a small 12-week study of rentosertib for idiopathic pulmonary fibrosis, six independent aging clocks all indicated the patients' blood appeared biologically younger, with four-week reductions of about 2.7–3.5 years on some clocks, but the findings are limited by the small sample size and potential disease-improvement effects, so they do not prove anti-aging effects and require larger, longer trials.
- AI-Designed Drug Makes Patients' Blood Look Biologically Younger, Study Shows ScienceAlert
- Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment Nature
- Drug developed for lung disease may slow biological aging in surprising ‘bonus’ Fox News
- Insilico’s Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too WSJ
- Early Data Indicates an A.I.-Generated Drug Could Slow Aging The New York Times
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
6 min
vs 7 min read
Condensed
96%
1,315 → 59 words
Want the full story? Read the original article
Read on ScienceAlert